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Summary Recent studies have shown that bafilomycin A,-sensitive vacuolar-type H'-ATPase (V-ATPase)
plays important roles in cell growth and differentiation. However, there is no published study that has focused
on the expression ofV-ATPase in human tumour tissues. This study was designed to examine the mRNA and
protein levels for the 16 kilodalton (kDa) proteolipid ofV-ATPase in human pancreatic carcinoma tissues. We
first investigated the mRNA level for V-ATPase in six cases of invasive pancreatic cancers and two normal
pancreases, using reverse transciption-polymerase chain reaction technique. Then, we examined
immunohistochemically the level of V-ATPase protein in 49 pancreatic cancers and ten benign cystic
neoplasms ofthe pancreas, using antisera raised against the 16 kDa proteolipid. There was a notable difference
in the level of V-ATPase mRNA between normal and pancreatic carcinoma tissues, with no evident difference
in the expression of the f-actin gene. Immunohistochemically, 42 out of 46 invasive ductal cancers (92%)
displayed a mild to marked immunoreactivity for V-ATPase in the cytoplasm, whereas neither non-invasive
ductal cancers nor benign cystic neoplasms expressed detectable immunoreactive proteins. These findings
suggest that the overexpression ofV-ATPase protein is characteristic ofinvasive pancreatic tumours. V-ATPase
may play some crucial roles in tumour progression.
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Recent studies have suggested that vacuolar type H+-ATPase
(V-ATPase), which has a molecular structure and drug
sensitivities distinct from mitochondrial F,F,-type ATPase
(F-ATPase) and gastric (H+K+)-ATPase (P-ATPase), is
responsible for the acidification of intracellular compartments
in eukaryotic cells. This acidification is crucial for a variety of
cellular processes including receptor-mediated endocytosis,
intracellular membrane traffic, macromolecular processing
and degradation and coupled transport in vacuolar compart-
ments (Forgac, 1989; Nelson, 1991; Forgac, 1992). V-ATPase
has been purified from endomembrane systems including
lysosomes, chromaffin granules, endosomes, synaptic vesicles
and clathrin-coated vesicles (Mellman et al., 1986; Arai et al.,
1987a; Nelson, 1989; Moriyama and Nelson, 1989; Moriyama
and Futai, 1990, Arai et al., 1993). In addition, V-ATPase
also has been detected in the plasma membrane of a few
specalised cell types including osteoclasts (Baron et al., 1985;
Akisaka and Gay, 1986; Vaananen et al., 1990), macrophages
(Swallow et al., 1990; Bidani and Brown, 1992; Tapper and
Sundler, 1992), activated neutrophils (Nanda et al., 1992),
renal intercalated cells (Verlander et al., 1991) and some
tumour cell lines (Martinez-Zaguilan et al., 1991).
V-ATPase is composed of two cytosolic (V1) and
transmembrane (VO) domains (Bowman et al., 1989;
Moriyama et al., 1992). The V1 domain is composed of a
hexamer of three subunit A proteins (65-75 kDa) and three
subunit B proteins (55-60 kDa) plus accessory subunits C, D
and E, which altogether form an approximately 500 kDa
complex with the structure A3B3CIDIE1 (Arai et al., 1988;
Adachi et al., 1990). The V1 domain, although not active as
an ATPase, contains both the catalytic and non-catalytic
nucleotide binding sites located on the A and B subunits
respectively (Manolson et al., 1985; Feng and Forgac, 1992).
The role of accessory subunits C, D and E in V-ATPase
function is not fully understood, although a combination of
purified subunits A, B, C and E promotes the ATPase
activity of the V1 subcomplex in vitro and strong evidence
suggests that the V1 subcomplex is actually involved in the
formation of functional H+-ATPase through attachment to
the membrane-embedded V0 domain (Xie and Stone, 1988;
Puopolo and Forgac, 1990). On the other hand, the V0
domain contains subunits ofmolecular mass 116 (or 100), 38,
19 and 16 kDa and forms an approximately 270 kDa
complex with the structure 1161381191166 (Puopolo and
Forgac, 1990; Zhang et al., 1992). Among these subunits,
the 16 kDa subunit (proteolipid) is considered to be an
essential component of the membrane sector which is
responsible for conducting protons across membranes (Arai
et al., 1987b; Sun et al., 1987; Kaestner et al., 1988).
Bafilomycin A1, a 16-membered macrolide antibiotic
isolated from Streptomyces griseus, has been identified as a
potent selective inhibitor of V-ATPases, causing complete
inhibition in vitro at nanomolar concentrations (Bowman et
al., 1988). It has been demonstrated that bafilomycin A, can
inhibit the growth of a variety of cultured cells in a dose-
dependent manner (Nelson and Nelson, 1990; Ohkuma et al.,
1993; Manabe et al., 1993). The results suggested that the pH
maintenance of acidic compartment driven by V-ATPase is
necessary for cell proliferation and its perturbation by
bafilomycin A1 results in the suppression of cell prolifera-
tion. However, the precise mechanisms by which bafilomycin
Al suppresses the proliferation of various cultured cells when
added to the culture medium have not yet been clarified
(Ohkuma et al., 1993). Furthermore, to our knowledge, there
is no published study that has focused on the expression of
V-ATPases in human tumour tissues.
In this study, we first picked up the 16 kDa subunit of
human V-ATPase which is one of the best documented and
most critical subunits of V-ATPases (Arai et al., 1987b; Sun
et al., 1987), and examined the mRNA and protein levels for
the 16 kDa subunit in human pancreatic carcinoma tissues by
light microscopic immunohistochemistry and reverse tran-
scription-polymerase chain reaction (RT-PCR) technique.
We used human pancreatic carcinoma tissues in this study for
the following reasons: (1) human pancreatic cancers, which
are among the most aggressive solid tumours in humans
(Nagai et al., 1986; Ohta et al., 1993) overexpress many
growth factors and their receptors, including epidermal
growth factor, basic fibroblast growth factor, acidic
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fibroblast growth factor and their receptors (Kobrin et al.,
1993; Lemoine et al., 1993; Yamanaka et al, 1993; Leung et
al., 1994); (2) these growth factors and their receptors are
considered to be internalised by endocytosis and pass through
endosomal and lysosomal compartments of decreased pH
(Forgac, 1989; Nelson, 1991; Forgac, 1992); and (3) among
these growth factors, basic fibroblast growth factor is
considered to enter the nucleus through acidic vesicles
before it promotes cell growth (Bouche et al., 1987). These
findings have led to the hypothesis that human pancreatic
cancers might overexpress V-ATPase in the endomembrane
system and possibly in the plasma membrane. In this paper,
we have found that almost all invasive pancreatic ductal
cancers display mild to marked immunoreactivity for the
16 kDa subunit of V-ATPase diffusely in the cytoplasm,
whereas none of the non-invasive pancreatic ductal cancers or
benign cystic neoplasms of the pancreas expressed detectable
V-ATPase immunoreactive proteins. These results suggest
that V-ATPase might play some crucial roles in tumour
progression.
Materials and methods
Tissue specimens
The current study included 49 surgically resected pancreatic
ductal adenocarcinomas between 1988 and 1994. A total of
46 tumours were histologically verified to be pancreatic
invasive tubular and/or papillary adenocarcinoma, while the
other three represented an intraductal variant of pancreatic
papillary adenocarcinoma without stromal invasion. There
were no cases of periampullary tumours or distal bile duct
tumours not originating from the pancreatic duct. The
patients included 30 men and 19 women, ranging from 33
to 78 years of age, with *a mean age of 62 years.
Histologically normal pancreatic tissues were obtained from
three male and two female patients undergoing pancreato-
duodenectomy for benign biliary disease. In addition, ten
cases of benign cystic neoplasms of the pancreas including
eight mucinous cystadenomas and two serous cystadenomas
were examined for comparative study. Immediately following
surgical removal, the tissue samples were fixed in 10%
neutral-buffered formalin and embedded in paraffin for
histological analysis. Three representative sections were used
for immunohistochemical staining as described below. More
recently six cases with pancreatic cancer and two cases with
normal pancreas had parallel samples frozen immediately in
liquid nitrogen for subsequent RT-PCR and immunopreci-
pitation analysis. Histological findings were evaluated
according to the General Rules for Cancer of the Pancreas
proposed by the Japanese Pancreatic Society (1986). Three
patients were stage I, five were stage II, 17 were stage III and
24 were stage IV. The adenocarcinoma was well differentiated
in 20 patients, moderately differentiated in 26 and poorly
differentiated in three patients.
PCR primers and probes
The following sets of oligonucleotide primers were synthe-
sised and used for the amplification reaction according to the
cDNA sequence of human 16 kDa subunit (Gillespie et al.,
1991). The 16 kDa subunit primers amplified a 446 bp
fragment: sense primer (16k-1), 5'-ATGTCCGAGTCCAA-
GAGCGG-3' (position 1-20); and antisense primer (16k-2),
5'-GCGACGATGAGACCGTAGAG-3' (position 427-446).
The f-actin primers amplified a 592 bp fragment: sense
pnmer (-1i), 5'-GAAAATCTGGCACCACACC-1--3' (posi-
tion 1299- 1319); and antisense primer (fl-2), 5'-GTTG
AAGGTAGTTrCGTGGAT-3' (position 2406
-2426). The
PCR probes used were 5'-GGCGATGAGGACTGCCAC-
CACCAGGCCGTAGAT-3' (position 199-231) for 16 kDa
subunit and 5'-GATCTlTCATGAGGTAGTCAGT-3' (posi-
tion 2047 -2067) for f-actin. These sequences ofPCR primers
and oligonucleotide probes were confirmed by GenBank
database to possess no homology with any other known
sequence. These synthetic oligonucleotide primers and probes
were purchased from Japan Bio Service (Niiza, Japan)
RNA isolation
Total RNA was isolated by the hot phenol guanidium
thiocianate method (Wang and Cox, 1968) from the
surgically resected specimens stored at -80-C. After a
quality check by agarose gel electrophoresis, the isolated
RNAs were immediately subjected to reverse transcriptase
(RT) reactions.
RT-PCR
First strand cDNA synthesis was performed as recommended
by the manufacturer (Sambrook et al., 1989) with slight
modifications. Briefly, 1 pg of total RNA was denatured at
65°C for 10 min and incubated at 42-C for 90 min in RT
buffer containing oligo-dT primers, dNTPs, RNAase
inhibitors and 200 U of Molony murne leukaemia virus
RT in a final volume of 20 p1 (Clontech Laboratories, Palo
Alto, CA, USA), followed by boiling for 5 min. Four
microlitres out of each RT reaction mixture were diluted up
to 100 pl and subjected to PCR amplification. The conditions
for amplification using AmpliTaq DNA polymerase (Perkin-
Elmer Cetus Instruments, Norwalk, CN, USA) were as
follows: denaturation 94°C for 30 s, annealing 60 C for 1 min
and extension 72'C for 2 min. The PCR products were
electrophoresed in 1.5% agarose gel, denatured in 0.2 N
sodium hydroxide solution, neutralised and transferred to a
nylon membrane (Pall BioSupport, East Hills, NY, USA).
The membrane was then hybridised to a specific anti-sense
oligonucleotide probe which was labelled by [_-3-2P]dCTP at
the 3 end (Numata et al., 1994). The final condition of
stringency of the washing was 1 xstandard saline citrate
buffer (SSC) containing 0.1% sodium dodecyl sulphate (SDS)
for 15 min at 60(C. The density of bands was measured by
Fuji image analyser BAS 2000 after exposure of the
membranes to Kodak XAR film.
Anti-16 kDa subunit antisera
The anti-16 kDa subunit antisera specific for the N-terminus
of the rat liver 16 kDa V-ATPase protein has recently been
obtained (Finbow et al., 1993). These antisera were raised in
rabbits by injecting the synthetic peptide, NH2-Asn-Pro-Glu-
Tyr-Ser-Ser-Phe-Phe-Cys-COOH which was coupled with
keyhole limpet haemocyanin (KLH; Sigma) by maleimido-
benzoyl-N-hydroxysuccinimide ester (MBS) method accord-
ing to the established procedure (Harlow and Lane, 1988). In
this study, we used these antisera instead of the antisera
against human 16 kDa V-ATPase protein for the following
reasons: (1) the synthetic peptide used in the present study is
closely similar to the N-terminus of human 16 kDa subunit
(Nezu et al., 1992); (2) the specificity of the primary antisera
has already been characterised by Finbow et al. (1993); and
(3) these pnrmary antisera immunoprecipitated the 16 kDa
subunit of human pancreatic cancer tissues selectively as well
as that of the rat liver lysosomes as shown in the 'Results',
indicating that these primary antisera can cross-react with
human 16 kDa subunit. Unfortunately, these primary
antisera were not adequate for Western blotting analysis.
Immunoprecipitation and SDS-PAGE
Human pancreatic cancer tissues which were stored at -80 C
were homogenised in lysis buffer [1% Triton X-100, 0.2%
SDS, 150 m-m sodium chloride, 1 mM magnesium chloride,
1 mM ethylene glycol-bis-tetraacetic acid (EGTA), 10 mM 2-
mercaptoethanol, 15 mM Tris-CI (pH 7.4)] containing
5 pg ml-' protease inhibitors (chymostatin, leupeptin, anti-
pain and pepstatin) and 1 mM phenylmethylsulphonyl
fluoride (PMSF). The 20% homogenate was vortexed for15 s, incubated on ice for 10 min and then sedimented at
106 000 x g for 1 h. The resulting supernatant was used as
the solubilised fraction for immunoprecipitation. Briefly, the
solubilised antigen and antibody were incubated for 2 h at
4-C under orbital shaking in 1.5 ml microcentrifuge tubes
precoated with 0.1% bovine serum albumin (BSA) in Tris-
buffered saline (TBS). The mixtures were added with 100 p1
of 25 mg ml- protein A sepharose in TBS, incubated for 1 h
at 40C, washed with TBS Tween 20 and centrifugated for 30 s
at 8500 x g. Then, the supernatant was carefully removed by
aspiration. After washing twice, the precipitate was
resuspended in 10 p1 of sampling buffer [4% SDS, 174 mM
Tris-HCI (pH 6.8), 5% glycerol, 0.2% bromophenol blue]
with 2-mercaptoethanol, incubated at 37-C for 1 h and
applied onto the electrophoresis in 15% SDS-PAGE. Proteins
were stained with Coomassie brilliant blue. The molecular
weight markers used were hen egg ovalbumin (45000), bovine
carbonic anhydrase (31 000), soybean trypsin inhibitor
(21500) and hen egg lysozyme (14400) (Sigma).
Light microscopic immunohistochemistry
Immunohistochemistry was performed using a three-step
indirect immunoperoxidase method (streptavidin-biotin-
peroxidase complex). Briefly, 4-pm-thick sections were
mounted on poly-L-lysine-coated glass slides, air dried and
deparaffinised with graded xylene and alcohol solutions.
Then, protease digestion was applied using protease K
(Boehringer Mannheim Biochemica, Germany) at a concen-
tration of 40 pgml-' for 5 min at 370C to facilitate
penetration of the primary antibody (Hughes and Hall,
1993). Following a phosphate-buffered saline (PBS) rinse, the
sections were immersed in absolute methanol containing
0.3% hydrogen peroxide (H202) to block endogenous
peroxidase activity and incubated with normal goat serum
at a 1:30 dilution for 30 min at room temperature to block
non-specific binding. Anti-16 kDa V-ATPase antisera were
diluted in PBS/0.3% BSA and used at the predetermined
optimal dilution. After overnight incubation at 4°C, the
sections were rinsed in PBS and incubated for 2 h at room
temperature with a biotinylated goat anti-rabbit IgG
(Dakopatts, Copenhagen, Denmark). The peroxidase-
labelled streptavidin (Dakopatts) was then added for
30 min at room temperature. The coloured reaction products
were developed by immersing the sections in a 3.3-
diaminobenzidine tetrahydrochloride solution containing
0.1% H202. The slides were counterstained lightly with
methyl green. In each immunostaining run, the primary
antisera were replaced by non-immune normal mouse serum
V-ATPas in pacre-ic cancer
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(Dako, Santa Barbara, CA, USA) as negative controls.
Sections from human normal pancreas were used as positive
controls because the islet cells showed positive staining as
shown in the 'Results'. In addition, the specificity of
immunostaining was also confirmed by a competitive
inhibition test using the synthetic peptide; primary antisera
were mixed with the synthetic peptide (1 pg ml-') and
followed by the immunostaining.
Quantification ofimmunohistochemical stainingfor the 16 kDa
V-ATPase protein
The degree ofprimary antisera reactivity on individual tissue
sections was scored semi-quantitatively (percentage of stained
carcinoma cells in the section) by two authors (TO and YT).
Tumours with more than 5% stained cells were defined as
positive and all others as negative. The proportion of
positively stained tumour cells was subdivided as follows:
minimal (+) denotes 5-25% of cells positive, moderate
(+ +) denotes 25-50% of cells positive, and marked
(+ + +) denotes more than 50% of cells positive.
Cancer Normal
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Figre 2 Southem blot analysis of PCR amplified products of
mRNA in human pancreatic ductal cancer and normal pancreas
with probes for 16kDa proteolipid (subunit) of V-ATPase and fi-
actin. A notable difference was evident in the expression of
16kDa proteolipid gene between pancreatic cancer and normal
tissues, with no obvious difference in the expression of the f-actin
gene. Lanes 1 -6, pancreatic cancer-, lanes 7 and 8, normal
pancreas.
CIO
c
(D
13
cr
Cycle numbers
Fiue 1 Determination of the exponential phase of amplifica-
tion in PCR reaction. We used 25 cycles for l6kDa proteolipid
(subunit) of V-ATPase (-0-) and 18 cycles for Il-actin (-O-) to
examine the expression levels of these genes.
Table I Relative amount ratio of RT-PCR products between
16kDa proteolipid of V-ATPase and fl-actin in tumour samples and
normal pancreas
Sanple nunbera 16kDa proteolipid, -actin
Pancreatic cancer
1 (case 37)b 15.63+ 1.44c
2(case20) 16.37+1.70
3 (case 38) 19.61 +1.43
4 (case 40) 17.48 +1.35
5 (case 36) 10.78+0.27
6 (case 39) 15.00+0.77
Normal pancreas
7 1.48+0.51
8 2.62+0.25
The relative amount ratio of RT-PCR products between 16kDa
proteolipid and fi-actin was determined using densitometric analysis.
aSample number corresponds to that in Figure 2. bCa number in
parenthesis corresponds to that in Table II. cThe results are expressed
as the mean+s.d. ofthree independent RT-PCR determinations.
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Figue 3 Immunoprecipitation of 16kDa proteolipid (subunit).
Human pancreatic cancer tissue extract (50jg protein) was
immunoprecipitated using protein A-coupled Sepharose either
with immune (lane 4) or with preimmune (lane 5) serum as
described under 'Materials and methods'. As positive control, rat
liver lysosomal membrane ghosts (20pg protein) were also
immunoprecipitated (lane 2). Immunoprecipitates were applied
onto 15% SDS-PAGE and stained with Coomassie brilliant blue.
Arrow indicates the immunospecific precipitate of 16kDa
proteolipid of V-ATPase. Several protein bands of higher
molecular weight represent serum proteins (immunoglobulins)
adsorbed to protein A-Sepharose which was used to facilitate
immunoprecipitation. Lane 1, molecular size marker-, lane 3,
extract of human pancreatic cancer tissue.
Results
Expression ofmRNA for 16 kDa subunit of V-ATPase in
hwnan pancreatic cancer
The amount of RNA is proportional to the amplified PCR
products only during the exponential phase ofDNA synthesis
(Chelly et al., 1988). Therefore, we first determined the
exponential phase of DNA synthesis (Figure 1). From this
result, we used 25 cycles for V-ATPases and 18 cycles for fi-
actin as the best condition to determine the expression levels
of these genes.
We first investigated the relative amount ratio of RT-
PCR products between the 16 kDA-subunit of human V-
ATPase and f-actin in six selected cases of human pancreatic
ductal cancers and two normal pancreases. Two normal
pancreas samples were obtained from another source as
described under 'Materials and methods' because it was
extremely difficult to obtain total RNAs from the small
amount of the non-cancerous normal pancreatic tissue
sample. As shown in Figure 2, a notable difference was
evident in the expression of the mRNA for 16 kDa subunit
between normal and pancreatic carcinoma tissues. There was
no evident difference in the expression of the f-actin gene.
Densitometrical analysis revealed that the degree of the
expression level of the 16 kDa subunit was approximately
eight times higher in cases with pancreatic cancer than in
normal pancreas (Table I).
Expression of 16 kDa subunit protein of V-ATPase in human
pancreatic cancer
The primary antisera raised against synthetic peptide
corresponding to the N-terminus of the rat liver 16 kDa
subunit protein immunoprecipitated selectively the 16 kDa
subunit ofhuman pancreatic cancer tissues (Figure 3), as well
as that of rat liver lysosome. Several protein bands of
molecular weight higher than the 16 kDa subunit found in
the immunoprecipitates represent serum proteins (mostly of
immunoglobulins) adsorbed to protein A-Sepharose, and
were not observed when immunoprecipitation was performed
without protein A-Sepharose (data not shown).
d
Figue 4 Light microscopic immunostaining for 16kDa proteo-
lipid of V-ATPase in human pancreatic tumours. (a) In normal
pancreas, a marked V-ATPase immunoreactivity is observed in
islet cells (original magnification x 200). (b) Mucinous cystadeno-
ma cells do not express V-ATPase immunoreactive proteins.
However, adjacent islet cells are stained intensely (original
magnifiction x 200). (c and d) Moderately and poorly differ-
entiated tubular adenocarcinoma cells display moderate to
marked immunoreactivity for V-ATPase protein diffusely in the
cytoplasm respectively (original magnification x 200).
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In all sections of normal pancreas samples, a marked V-
ATPase immunoreactivity was observed in islet cells (Figure
4a), whereas immunostaining was not observed in acinar or
ductal cells. Therefore, we used the islet cells as positive
internal controls in this study. In each immunostaining run,
to test for the specificity of immunostaining, the primary
antisera were replaced by non-immune normal mouse serum
in the first reaction and a competitive inhibition test was also
performed that resulted in no detectable staining.
The immunohistochemical staining and its quantification
of V-ATPase protein in human pancreatic tumour specimens
are shown in Figure 4b-d) and summarsed in Table II. A
total of 42 out of 46 invasive tubular or papillary
adenocarcinomas (92%) displayed mild to marked immunor-
eactivity to V-ATPase (Figure 4c and 4d). The immuno-
reactive pattern was finely granular and was generally present
diffusely in the cytosplasm of carcinoma cells. The intensity
of V-ATPase immunoreactivity showed heterogeneity both
between and within cases. Usually its immunoreactivity was
more pronounced at the infiltrative margins of the tumours.
In contrast, three intraductal (non-invasive) papillary
adenocarcinomas did not express detectable V-ATPase
immunoreactive proteins, whereas adjacent normal islet cells
were stained intensely. In addition, all ten benign cystic
neoplasms of the pancreas did not express V-ATPase
immunoreactive proteins (Figure 4b). In non-tumorous
tissues, only the islet cells displayed a marked immunor-
eactivity for V-ATPase protein as well as in normal
pancreatic tissues. The expression level of V-ATPase protein
paralleled well with that of V-ATPase mRNA in six cases
with human pancreatic ductal cancer that were subjected to
RT-PCR analysis (Tables I and II).
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Disassio
In this study, we postulated that pancreatic ductal cancers
might overexpress V-ATPases. Accordingly, we first investi-
gated the level of mRNA expression for the 16 kDa subunit
of human V-ATPases in six selected cases of human
pancreatic ductal carcinomas and two normal pancreases,
using RT-PCR analysis which is a more sensitive method
requiring a smaller amount of sample than Northern blot or
dot/slot blot analysis. In our experience, RT-PCR is the
only applicable method to quantitate RNAs from a limited
amount of isolated RNAs because the surgically resected
pancreatic cancer tissues are relatively hard with fibrotic
changes, and the amount of total RNA isolated from such
specimens is comparatively small. In our RT-PCR assay, a
notable difference was evident in the expression of the
mRNA for 16 kDa subunit of V-ATPase between normal
and pancreatic carcinoma tissues, despite no evident
difference in the expression of the f-actin gene, indicating
that human pancreatic cancer tissues could overexpress V-
ATPase proteins. Unfortunately, we could not establish the
levels of V-ATPase with any degree of certainty in either
pancreatic cancer tissue or non-cancerous tissue groups, since
it was extremely difficult to obtain total RNAs from the small
amount of non-cancerous tissues.
These findings prompted us to examine closely the
distribution and localisation of V-ATPase in normal
pancreas, pancreatic carcinoma tissues and adjacent non-
cancerous pancreatic tissues by immunohistochemistry, using
antisera against the 16 kDa subunit. In the normal pancreas
and adjacent non-cancerous pancreatic tissues, most islet cells
were stained intensely with anti-V-ATPase antisera. On the
Table U Immunostaining of human pancreatic tumour specimens with anti-16kDa proteolipid of V-ATPase
antisera
V-ATPase V-ATPase
Case Stained Staining Case Stained Staining
number Age Sex Stage proportion intensity number Age Sex Stage proportion intensity
Serous cystadenoma 29 46 F III
1 64 M
- - - 30 69 F III + + W
2 74 F - - - 31 51 M III + W
Mucinous cystadenoma 32 77 M III + + W
3 71 M - - - 33 55 M III + w
4 74 M - - - 34 70 F III + W
5 59 M - - - 35 51 M III + + W
6 54 F - - - 36 62 M IV + + W
7 64 M - - - 37 71 M IV + + S
8 62 M - - - 38 48 M IV + + + S
9 77 F - - - 39 66 M IV + + S
10 64 F - - - 40 69 F IV + + + S
Non-invasive ductal adenocarcinoma 41 61 F IV + W
11 72 F I - - 42 54 M IV
12 58 M I - - 43 52 M IV + + W
13 62 F I - - 44 78 F IV ++ + S
Invasive ductal adenocarcinoma 45 39 F IV + + W
14 66 F n +++ w 46 69 F IV + W
15 54 F IH + + W 47 66 M IV + + + W
16 59 M II + W 48 76 M IV + + W
17 74 M H + + W 49 61 M IV + + S
18 57 M + ++ W 50 59 M IV + + W
19 53 F III +++ W 51 77 F IV + + + W
20 77 F ++ s 52 33 M IV
21 49 M In + + W 53 59 M IV
22 61 F II +++ W 54 66 M IV + + W
23 65 F II + W 55 67 M IV + + W
24 62 M HI + w 56 62 M IV + + + W
25 62 M HI ++ + S 57 57 M IV + + W
26 64 M HI + + W 58 70 F IV + W
27 69 F II + + S 59 69 M IV + + + S
28 60 M II + + S
Stainedproportion:-, all cellsnegative or <5% ofcellspositive; +,5 -25% ofcellspositive; + +, 25 -50% ofcels positive; +++, 50-100% ofcellspositive. Stainingintensity: -, no staining; W, weak intensity; S, strong intensity.V-ATPass i puiceatic cancer
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other hand, neither acinar cells nor pancreatic ductal epithelia
expressed detectable V-ATPase immunoreactive proteins. The
positively-stained islet cells were considered to be B-cells of
the pancreatic islets because the distribution of these positive
cells was similar to that of islet cells stained with an anti-
insulin monoclonal antibody (unpublished data). This
explanation was supported by the finding that acidic
clathrin-coated secretory vesicles were abundant in the
cytosol of B-cells of human pancreatic islets (Orci et al.,
1987, 1994). In the pancreatic cancer samples, approximately
90% of the invasive ductal adenocarcinomas displayed mild
to marked immunoreactivity for V-ATPase, whereas none of
the three intraductal (non-invasive) papillary adenocarcino-
mas displayed reactivity under light microscopic immunohis-
tochemistry. None of the ten benign cystic neoplasms of the
pancreas expressed V-ATPase immunoreactive proteins
either. In the invasive carcinoma cells, the immunoperox-
idase staining reaction product was distributed diffusely
throughout the cell, suggesting that V-ATPases are expressed
in the cytosolic acidic compartments like lysosomes,
endosomes and/or coated vesicles. The increased expression
of V-ATPase in the cytoplasm of carcinoma cells, however,
may be a secondary consequence of up-regulation of the
entire system of endocytic organelles like endosomes and
coated vesicles since lysosomes are rarely found in pancreatic
ductal cancers (Kern et al., 1987; Ghadially, 1988).
Furthermore, its immunoreactivity was usually more
pronounced at the infiltrative margins of the tumours. These
findings suggest that the overexpression of the 16 kDa
subunit of V-ATPase is characteristic of invasive pancreatic
tumours and V-ATPase may play some crucial and
specialised role in tumour progression. Our present data are
the first indication of V-ATPase expression in human
pancreatic cancer cells using surgically resected carcinoma
tissues. The expression of V-ATPase is, however, not specific
for pancreatic cancer because our preliminary study
demonstrated V-ATPase expression in other gastrointestinal
carcinomas including gastric and colon cancers (unpublished
data). Additional studies are currently in progress to
investigate the relationship between expression level of V-
ATPase protein and proliferative activity in pancreatic cancer
and other gastrointestinal carcinomas.
Recently, we have demonstrated the unique distribution of
mRNA for the 16 kDa subunit of V-ATPase at the sites of
epithelium-mesenchyme interaction and mesenchymal differ-
entiation during the later stage of rat embryogenesis as well
as in developing rat brain by in situ hybridisation (Numata et
al., 1995a,b). Therefore, our present results may also be
interpreted in the light of interactions between carcinoma
cells and surrounding stromal or normal epithelial cells.
Furthermore, the E5 oncoprotein of bovine papilloma virus
type 1 has been shown to bind selectively to the 16 kDa
subunit of V-ATPase and involves the ligand-independent
activation of growth factor receptor (Goldstein et al., 1992).
These findings suggest that 16 kDa subunit ofV-ATPase may
play an important role in tumour transformation through a
potential link between receptor signal transduction pathways
and membrane pore activity. The 16 kDa subunit has also
been shown to be expressed as a gap junction (Finbow et al.,
1994) and mediatophore (Israel et al., 1986). Therefore, we
cannot exclude the possibility of some novel functions of the
16 kDa subunit in pancreatic cancers besides its known
functions. In any case, precise intracellular localisation of
16 kDa subunit and other subunits is prerequisite for a better
understanding of functional importance of V-ATPase.
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